Enovis Corp (ENOV) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments.
Total Assets Chart for Enovis Corp
Enovis Corp (ENOV) total assets for FY2025 were USD 3.8B, a -18.7% change from FY2024. Enovis Corp's total assets grew from USD 707.9M in 2004 to USD 3.8B in 2025 (441.7% over 21 years). Total assets compound annual growth rate: 5-year CAGR of -12.2%, 10-year CAGR of -5.5%, 20-year CAGR of 8.9%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $1.22B
- Implied Share Price
- $21.08
- Enterprise Value
- $2.41B
- Revenue (TTM)
- $2.30B
- EBITDA
- $379.78M
- Profit Margin
- -47.97%
- Trailing P/E
- —
- Forward P/E
- 4.64
- Price/Book (MRQ)
- 0.71
- Price/Sales (TTM)
- 0.53
- EV/EBITDA
- 22.42
- EV/Revenue
- 1.05
- Dividend Yield
- —
- Book Value
- $25.61
- Free Cash Flow (FY2025)
- $19.92M
- Free Cash Flow Yield
- 1.64%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.